Software - Infrastructure
Compare Stocks
5 / 10Stock Comparison
DOX vs CTSH vs ACN vs INFY vs IBM
Revenue, margins, valuation, and 5-year total return — side by side.
Information Technology Services
Information Technology Services
Information Technology Services
Information Technology Services
DOX vs CTSH vs ACN vs INFY vs IBM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Software - Infrastructure | Information Technology Services | Information Technology Services | Information Technology Services | Information Technology Services |
| Market Cap | $6.91B | $24.49B | $112.34B | $52.03B | $215.52B |
| Revenue (TTM) | $4.58B | $21.41B | $72.11B | $19.85B | $68.91B |
| Net Income (TTM) | $572M | $2.23B | $7.68B | $3.21B | $10.75B |
| Gross Margin | 37.6% | 32.1% | 32.0% | 30.0% | 59.0% |
| Operating Margin | 17.7% | 15.7% | 14.8% | 20.3% | 16.4% |
| Forward P/E | 8.5x | 9.1x | 13.0x | 16.8x | 18.5x |
| Total Debt | $826M | $1.57B | $8.18B | $962M | $67.15B |
| Cash & Equiv. | $325M | $1.90B | $11.48B | $2.86B | $13.64B |
DOX vs CTSH vs ACN vs INFY vs IBM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Amdocs Limited (DOX) | 100 | 102.4 | +2.4% |
| Cognizant Technolog… (CTSH) | 100 | 97.5 | -2.5% |
| Accenture plc (ACN) | 100 | 89.5 | -10.5% |
| Infosys Limited (INFY) | 100 | 141.0 | +41.0% |
| International Busin… (IBM) | 100 | 192.6 | +92.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DOX vs CTSH vs ACN vs INFY vs IBM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
DOX ranks third and is worth considering specifically for stability.
- Beta 0.53 vs IBM's 1.00, lower leverage
CTSH is the clearest fit if your priority is sleep-well-at-night and valuation efficiency.
- Lower volatility, beta 0.71, Low D/E 10.5%, current ratio 2.34x
- PEG 0.75 vs INFY's 2.52
- Lower P/E (9.1x vs 18.5x), PEG 0.75 vs 1.49
ACN is the clearest fit if your priority is income & stability.
- Dividend streak 14 yrs, beta 0.80, yield 3.2%
INFY carries the broadest edge in this set and is the clearest fit for defensive.
- Beta 0.86, yield 4.5%, current ratio 2.27x
- 16.2% margin vs CTSH's 10.4%
- 4.5% yield, 4-year raise streak, vs IBM's 2.9%
- 18.6% ROA vs IBM's 7.1%, ROIC 31.8% vs 9.8%
IBM is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 7.6%, EPS growth 73.7%, 3Y rev CAGR 3.7%
- 108.0% 10Y total return vs INFY's 76.2%
- 7.6% revenue growth vs DOX's -9.4%
- -6.3% vs ACN's -39.5%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 7.6% revenue growth vs DOX's -9.4% | |
| Value | Lower P/E (9.1x vs 18.5x), PEG 0.75 vs 1.49 | |
| Quality / Margins | 16.2% margin vs CTSH's 10.4% | |
| Stability / Safety | Beta 0.53 vs IBM's 1.00, lower leverage | |
| Dividends | 4.5% yield, 4-year raise streak, vs IBM's 2.9% | |
| Momentum (1Y) | -6.3% vs ACN's -39.5% | |
| Efficiency (ROA) | 18.6% ROA vs IBM's 7.1%, ROIC 31.8% vs 9.8% |
DOX vs CTSH vs ACN vs INFY vs IBM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
DOX vs CTSH vs ACN vs INFY vs IBM — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
CTSH leads in 1 of 6 categories
INFY leads 1 • IBM leads 1 • DOX leads 0 • ACN leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — INFY and IBM each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ACN is the larger business by revenue, generating $72.1B annually — 15.7x DOX's $4.6B. INFY is the more profitable business, keeping 16.2% of every revenue dollar as net income compared to CTSH's 10.4%. On growth, IBM holds the edge at +9.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $4.6B | $21.4B | $72.1B | $19.8B | $68.9B |
| EBITDAEarnings before interest/tax | $1.0B | $3.9B | $12.1B | $4.3B | $15.1B |
| Net IncomeAfter-tax profit | $572M | $2.2B | $7.7B | $3.2B | $10.8B |
| Free Cash FlowCash after capex | $755M | $2.5B | $12.5B | $3.8B | $13.1B |
| Gross MarginGross profit ÷ Revenue | +37.6% | +32.1% | +32.0% | +30.0% | +59.0% |
| Operating MarginEBIT ÷ Revenue | +17.7% | +15.7% | +14.8% | +20.3% | +16.4% |
| Net MarginNet income ÷ Revenue | +12.5% | +10.4% | +10.7% | +16.2% | +15.6% |
| FCF MarginFCF ÷ Revenue | +16.5% | +11.5% | +17.3% | +19.2% | +19.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +4.1% | +5.8% | +8.3% | +3.2% | +9.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +9.0% | +3.7% | +3.9% | -5.3% | +14.3% |
Valuation Metrics
CTSH leads this category, winning 6 of 7 comparable metrics.
Valuation Metrics
At 11.4x trailing earnings, CTSH trades at a 45% valuation discount to IBM's 20.6x P/E. Adjusting for growth (PEG ratio), CTSH offers better value at 0.94x vs INFY's 2.53x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $6.9B | $24.5B | $112.3B | $52.0B | $215.5B |
| Enterprise ValueMkt cap + debt − cash | $7.4B | $24.2B | $109.0B | $50.1B | $269.0B |
| Trailing P/EPrice ÷ TTM EPS | 12.62x | 11.36x | 14.85x | 16.88x | 20.57x |
| Forward P/EPrice ÷ next-FY EPS est. | 8.55x | 9.07x | 13.00x | 16.84x | 18.47x |
| PEG RatioP/E ÷ EPS growth rate | 1.98x | 0.94x | 1.65x | 2.53x | 1.66x |
| EV / EBITDAEnterprise value multiple | 7.28x | 5.92x | 8.61x | 10.80x | 17.53x |
| Price / SalesMarket cap ÷ Revenue | 1.53x | 1.16x | 1.61x | 2.70x | 3.19x |
| Price / BookPrice ÷ Book value/share | 2.05x | 1.66x | 3.54x | 4.73x | 6.66x |
| Price / FCFMarket cap ÷ FCF | 10.72x | 9.44x | 10.33x | 12.73x | 18.62x |
Profitability & Efficiency
INFY leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
IBM delivers a 35.4% return on equity — every $100 of shareholder capital generates $35 in annual profit, vs $15 for CTSH. INFY carries lower financial leverage with a 0.09x debt-to-equity ratio, signaling a more conservative balance sheet compared to IBM's 2.05x. On the Piotroski fundamental quality scale (0–9), DOX scores 6/9 vs IBM's 5/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +16.5% | +14.8% | +23.9% | +29.6% | +35.4% |
| ROA (TTM)Return on assets | +9.0% | +10.9% | +11.8% | +18.6% | +7.1% |
| ROICReturn on invested capital | +15.6% | +18.7% | +26.8% | +31.8% | +9.8% |
| ROCEReturn on capital employed | +16.8% | +21.1% | +24.9% | +33.5% | +9.5% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 | 5 | 5 | 5 |
| Debt / EquityFinancial leverage | 0.24x | 0.10x | 0.25x | 0.09x | 2.05x |
| Net DebtTotal debt minus cash | $501M | -$326M | -$3.3B | -$1.9B | $53.5B |
| Cash & Equiv.Liquid assets | $325M | $1.9B | $11.5B | $2.9B | $13.6B |
| Total DebtShort + long-term debt | $826M | $1.6B | $8.2B | $962M | $67.2B |
| Interest CoverageEBIT ÷ Interest expense | 23.45x | 107.78x | 40.67x | 90.32x | 6.41x |
Total Returns (Dividends Reinvested)
IBM leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IBM five years ago would be worth $18,832 today (with dividends reinvested), compared to $7,076 for ACN. Over the past 12 months, IBM leads with a -6.3% total return vs ACN's -39.5%. The 3-year compound annual growth rate (CAGR) favors IBM at 26.8% vs ACN's -9.3% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -19.8% | -36.0% | -29.3% | -29.3% | -20.0% |
| 1-Year ReturnPast 12 months | -28.8% | -33.2% | -39.5% | -23.7% | -6.3% |
| 3-Year ReturnCumulative with dividends | -22.9% | -10.3% | -25.4% | -5.9% | +103.8% |
| 5-Year ReturnCumulative with dividends | -4.8% | -22.4% | -29.2% | -17.5% | +88.3% |
| 10-Year ReturnCumulative with dividends | +34.1% | -0.4% | +90.1% | +76.2% | +108.0% |
| CAGR (3Y)Annualised 3-year return | -8.3% | -3.5% | -9.3% | -2.0% | +26.8% |
Risk & Volatility
Evenly matched — DOX and IBM each lead in 1 of 2 comparable metrics.
Risk & Volatility
DOX is the less volatile stock with a 0.53 beta — it tends to amplify market swings less than IBM's 1.00 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IBM currently trades 70.7% from its 52-week high vs INFY's 42.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.53x | 0.71x | 0.80x | 0.86x | 1.00x |
| 52-Week HighHighest price in past year | $95.41 | $87.03 | $325.71 | $30.00 | $324.90 |
| 52-Week LowLowest price in past year | $62.75 | $50.19 | $172.52 | $12.16 | $220.72 |
| % of 52W HighCurrent price vs 52-week peak | +66.8% | +59.4% | +55.4% | +42.8% | +70.7% |
| RSI (14)Momentum oscillator 0–100 | 48.5 | 27.6 | 41.9 | 40.2 | 43.9 |
| Avg Volume (50D)Average daily shares traded | 962K | 5.8M | 5.6M | 16.1M | 5.3M |
Analyst Outlook
Evenly matched — INFY and IBM each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: DOX as "Buy", CTSH as "Hold", ACN as "Buy", INFY as "Hold", IBM as "Hold". Consensus price targets imply 66.2% upside for ACN (target: $300) vs 31.7% for INFY (target: $17). For income investors, INFY offers the higher dividend yield at 4.54% vs CTSH's 2.45%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Buy | Hold | Hold |
| Price TargetConsensus 12-month target | $90.00 | $81.75 | $299.92 | $16.90 | $309.64 |
| # AnalystsCovering analysts | 11 | 51 | 53 | 40 | 50 |
| Dividend YieldAnnual dividend ÷ price | +3.1% | +2.4% | +3.2% | +4.5% | +2.9% |
| Dividend StreakConsecutive years of raises | 12 | 9 | 14 | 4 | 30 |
| Dividend / ShareAnnual DPS | $2.01 | $1.27 | $5.85 | $0.58 | $6.59 |
| Buyback YieldShare repurchases ÷ mkt cap | +8.0% | +5.6% | +4.1% | 0.0% | 0.0% |
CTSH leads in 1 of 6 categories (Valuation Metrics). INFY leads in 1 (Profitability & Efficiency). 3 tied.
DOX vs CTSH vs ACN vs INFY vs IBM: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is DOX or CTSH or ACN or INFY or IBM a better buy right now?
For growth investors, International Business Machines Corporation (IBM) is the stronger pick with 7.
6% revenue growth year-over-year, versus -9. 4% for Amdocs Limited (DOX). Cognizant Technology Solutions Corporation (CTSH) offers the better valuation at 11. 4x trailing P/E (9. 1x forward), making it the more compelling value choice. Analysts rate Amdocs Limited (DOX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — DOX or CTSH or ACN or INFY or IBM?
On trailing P/E, Cognizant Technology Solutions Corporation (CTSH) is the cheapest at 11.
4x versus International Business Machines Corporation at 20. 6x. On forward P/E, Amdocs Limited is actually cheaper at 8. 5x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Cognizant Technology Solutions Corporation wins at 0. 75x versus Infosys Limited's 2. 52x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — DOX or CTSH or ACN or INFY or IBM?
Over the past 5 years, International Business Machines Corporation (IBM) delivered a total return of +88.
3%, compared to -29. 2% for Accenture plc (ACN). Over 10 years, the gap is even starker: IBM returned +108. 0% versus CTSH's -0. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — DOX or CTSH or ACN or INFY or IBM?
By beta (market sensitivity over 5 years), Amdocs Limited (DOX) is the lower-risk stock at 0.
53β versus International Business Machines Corporation's 1. 00β — meaning IBM is approximately 88% more volatile than DOX relative to the S&P 500. On balance sheet safety, Infosys Limited (INFY) carries a lower debt/equity ratio of 9% versus 2% for International Business Machines Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — DOX or CTSH or ACN or INFY or IBM?
By revenue growth (latest reported year), International Business Machines Corporation (IBM) is pulling ahead at 7.
6% versus -9. 4% for Amdocs Limited (DOX). On earnings-per-share growth, the picture is similar: International Business Machines Corporation grew EPS 73. 7% year-over-year, compared to 0. 0% for Infosys Limited. Over a 3-year CAGR, INFY leads at 5. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — DOX or CTSH or ACN or INFY or IBM?
Infosys Limited (INFY) is the more profitable company, earning 16.
4% net margin versus 10. 6% for Cognizant Technology Solutions Corporation — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INFY leads at 21. 1% versus 14. 7% for ACN. At the gross margin level — before operating expenses — IBM leads at 59. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is DOX or CTSH or ACN or INFY or IBM more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Cognizant Technology Solutions Corporation (CTSH) is the more undervalued stock at a PEG of 0. 75x versus Infosys Limited's 2. 52x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Amdocs Limited (DOX) trades at 8. 5x forward P/E versus 18. 5x for International Business Machines Corporation — 9. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ACN: 66. 2% to $299. 92.
08Which pays a better dividend — DOX or CTSH or ACN or INFY or IBM?
All stocks in this comparison pay dividends.
Infosys Limited (INFY) offers the highest yield at 4. 5%, versus 2. 4% for Cognizant Technology Solutions Corporation (CTSH).
09Is DOX or CTSH or ACN or INFY or IBM better for a retirement portfolio?
For long-horizon retirement investors, Amdocs Limited (DOX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
53), 3. 1% yield). Both have compounded well over 10 years (DOX: +34. 1%, IBM: +108. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between DOX and CTSH and ACN and INFY and IBM?
Both stocks operate in the Technology sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: DOX is a small-cap deep-value stock; CTSH is a mid-cap deep-value stock; ACN is a mid-cap deep-value stock; INFY is a mid-cap deep-value stock; IBM is a large-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.